Market Overview: GLP-1 Agonists and the Obesity Market

Market Overview: GLP-1 Agonists and the Obesity Market

Introduction to GLP-1 Agonists GLP-1 agonists have been pivotal in the pharmaceutical market for nearly two decades, beginning with the FDA approval of AstraZeneca’s Byetta in 2005. Since then, the landscape has seen numerous entries and exits, leaving Novo Nordisk...
Using Data to Optimize Clinical Trial Recruitment

Using Data to Optimize Clinical Trial Recruitment

The Importance of a High-Performing Clinical Trial Partnership Pharmaceutical companies are heavily dependent on clinical trials to assist with the placement, promotion, and sales of their products. If they are introducing a new mechanism of action (MOA) or modality...
New Developments in Alzheimer’s Treatment

New Developments in Alzheimer’s Treatment

OZMOSI’s predictions for where Alzheimer’s treatment is headed. The Ravaging Effects of Alzheimer’s The devastation of living with an Alzheimer’s diagnosis is exponentially affecting more and more people. A 2019 study conducted by The Lancet estimated 57 million...